Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BDMD NASDAQ:OSRH NASDAQ:POAI NASDAQ:VVOS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDMDBaird Medical Investment$3.12-1.6%$4.60$1.05▼$12.50$20.54M-0.94259,730 shs56,376 shsOSRHOSR$1.06+6.0%$1.30$1.00▼$13.40$20.43M1.56212,668 shs297,234 shsPOAIPredictive Oncology$0.79+1.1%$0.92$0.55▼$3.06$7.06M1.171.95 million shs183,640 shsVVOSVivos Therapeutics$5.82+1.6%$3.36$1.97▼$7.95$34.28M7.01620,299 shs268,282 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDMDBaird Medical Investment-1.58%-7.69%-51.63%-44.19%+311,999,900.00%OSRHOSR+6.00%-10.17%-34.57%-20.30%+105,999,900.00%POAIPredictive Oncology+1.09%0.00%-12.22%-15.55%-32.48%VVOSVivos Therapeutics+1.57%-14.66%+134.68%+177.14%+105.65%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBDMDBaird Medical InvestmentN/AN/AN/AN/AN/AN/AN/AN/AOSRHOSRN/AN/AN/AN/AN/AN/AN/AN/APOAIPredictive Oncology2.7183 of 5 stars3.05.00.00.03.40.00.6VVOSVivos Therapeutics0.8089 of 5 stars1.35.00.00.01.10.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBDMDBaird Medical Investment 0.00N/AN/AN/AOSRHOSR 0.00N/AN/AN/APOAIPredictive Oncology 2.00Hold$3.00279.75% UpsideVVOSVivos Therapeutics 2.50Moderate Buy$4.82-17.24% DownsideCurrent Analyst Ratings BreakdownLatest POAI, VVOS, OSRH, and BDMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2025VVOSVivos TherapeuticsIndustrial Alliance SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$2.255/20/2025VVOSVivos TherapeuticsAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBDMDBaird Medical InvestmentN/AN/AN/AN/AN/AN/AOSRHOSRN/AN/AN/AN/A($3.87) per shareN/APOAIPredictive Oncology$1.62M4.35N/AN/A($0.03) per share-26.33VVOSVivos Therapeutics$14.63M2.34N/AN/A$1.35 per share4.31Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBDMDBaird Medical InvestmentN/AN/A0.00∞N/AN/AN/AN/AN/AOSRHOSR-$2.41MN/A0.00∞N/AN/A-36.89%-19.14%N/APOAIPredictive Oncology-$12.66M-$3.05N/AN/AN/A-629.68%-671.29%-132.49%8/12/2025 (Estimated)VVOSVivos Therapeutics-$11.14M-$1.73N/AN/AN/A-76.82%-170.43%-77.82%8/13/2025 (Estimated)Latest POAI, VVOS, OSRH, and BDMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025VVOSVivos Therapeutics-$0.39N/AN/AN/A$3.37 millionN/A8/12/2025Q2 2025POAIPredictive Oncology-$0.09N/AN/AN/AN/AN/A5/20/2025Q1 2025OSRHOSRN/A-$1.04N/A-$1.04N/A$0.76 million5/15/2025Q1 2025VVOSVivos Therapeutics-$0.44-$0.45-$0.01-$0.45$3.63 million$3.70 million5/14/2025Q1 2025POAIPredictive Oncology-$0.09-$0.32-$0.23-$0.34$1.50 million$0.11 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBDMDBaird Medical InvestmentN/AN/AN/AN/AN/AOSRHOSRN/AN/AN/AN/AN/APOAIPredictive OncologyN/AN/AN/AN/AN/AVVOSVivos TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBDMDBaird Medical InvestmentN/AN/AN/AOSRHOSRN/A0.250.20POAIPredictive OncologyN/A0.760.75VVOSVivos TherapeuticsN/A0.770.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBDMDBaird Medical Investment19.78%OSRHOSR55.30%POAIPredictive Oncology9.04%VVOSVivos Therapeutics26.35%Insider OwnershipCompanyInsider OwnershipBDMDBaird Medical Investment78.90%OSRHOSR33.67%POAIPredictive Oncology3.44%VVOSVivos Therapeutics3.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBDMDBaird Medical InvestmentN/A6.58 million1.39 millionN/AOSRHOSRN/A19.28 million12.79 millionN/APOAIPredictive Oncology308.93 million8.63 millionNot OptionableVVOSVivos Therapeutics1605.89 million5.71 millionOptionablePOAI, VVOS, OSRH, and BDMD HeadlinesRecent News About These CompaniesVivos Therapeutics Receives Medicare Approval for VidaSleep™ Oral Appliance - MorningstarJuly 2, 2025 | morningstar.comMVivos Therapeutics Inc. (VVOS) Stock Price Today - WSJJuly 2, 2025 | wsj.comVivos Therapeutics Receives Medicare Approval for VidaSleep™ Oral ApplianceJuly 1, 2025 | taiwannews.com.twTVivos Therapeutics stock soars after Medicare approves VidaSleep oral applianceJuly 1, 2025 | in.investing.comVivos Therapeutics Shares Skyrocket After Medicare Greenlights VidaSleep Oral DeviceJuly 1, 2025 | msn.comVivos Therapeutics Secures CMS Approval for VidaSleep™ Oral Appliance, Expanding Access to Sleep Apnea TreatmentJuly 1, 2025 | quiverquant.comQNew Clinical Trial Data Published Showing Positive Results from Use of Vivos Technology to Treat Obstructive Sleep Apnea in ChildrenJune 26, 2025 | finance.yahoo.comNew Clinical Trial Data Published Showing Positive Results from Use of Vivos Technology to Treat Obstructive Sleep Apnea in ChildrenJune 26, 2025 | globenewswire.comVivos Therapeutics, Inc: Vivos Therapeutics Completes Acquisition of The Sleep Center of NevadaJune 11, 2025 | finanznachrichten.deVivos Therapeutics Completes Acquisition of The Sleep Center of NevadaJune 11, 2025 | finance.yahoo.comVivos Therapeutics Completes Acquisition of The Sleep Center of Nevada, Expanding OSA Diagnostic and Treatment CapabilitiesJune 11, 2025 | quiverquant.comQVivos Therapeutics Secures $1.1M Convertible NoteMay 23, 2025 | tipranks.comEarnings call transcript: Vivos Therapeutics reports Q1 2025 earnings, stock risesMay 17, 2025 | uk.investing.comVivos Therapeutics, Inc: Vivos Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational UpdateMay 17, 2025 | finanznachrichten.deVivos Therapeutics Inc (VVOS) Q1 2025 Earnings Call Highlights: Strategic Acquisitions and FDA ...May 17, 2025 | finance.yahoo.comVivos Therapeutics’ Earnings Call: Strategic Shifts Amid Financial ChallengesMay 16, 2025 | tipranks.comVivos Therapeutics, Inc. (VVOS) Q1 2025 Earnings Call TranscriptMay 15, 2025 | seekingalpha.comVivos Therapeutics, Inc. (VVOS) Reports Q1 Loss, Lags Revenue EstimatesMay 15, 2025 | zacks.comVivos Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational UpdateMay 15, 2025 | finance.yahoo.comVivos Therapeutics Schedules Release of First Quarter 2025 Financial Results and Conference CallMay 15, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePOAI, VVOS, OSRH, and BDMD Company DescriptionsBaird Medical Investment NASDAQ:BDMD$3.12 -0.05 (-1.58%) As of 07/18/2025 04:00 PM EasternBaird Medical Investment Holdings Ltd. is a medical technology company, which engages in the development and provision of medical devices. It is also involved in the design, development, manufacturing, and sale of microwave ablation medical devices, as well as sale of other medical devices. The company was founded on June 16, 2023 and is headquartered in Guangzhou, China.OSR NASDAQ:OSRH$1.06 +0.06 (+6.00%) As of 07/18/2025 03:41 PM EasternOSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D "platform technologies" versus "assets only" companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea.Predictive Oncology NASDAQ:POAI$0.79 +0.01 (+1.09%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$0.80 +0.01 (+1.27%) As of 07/18/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Predictive Oncology Inc. operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples. It operates through four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment provides services that include the application of AI, collaboration projects, and clinical testing. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using a self-contained automated system that conducts self-interaction chromatography screens using additives and excipients included in protein formulations resulting in soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is headquartered in Eagan, Minnesota.Vivos Therapeutics NASDAQ:VVOS$5.82 +0.09 (+1.57%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$5.80 -0.02 (-0.26%) As of 07/18/2025 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
